Out of 74 fetuses with LUTO evaluated at our institute, 34 fetuses with LUTO met our eligibility criteria. Baseline characteristics, details of the scoring parameters are presented in table 1. Overall the perinatal survival was 59%. According to the suggested scoring system, Scores 0 (all the 4 parameters within normal), 1 and 2 (one / two parameters are abnormal respectively) were associated with 66% perinatal survival while scores 3 and 4 (3 and 4 parameters are abnormal respectively) were associated with 0% perinatal survival. The ROC curve of the scoring system in determining the perinatal mortality yielded an AUC of 0.68 (95% CI 0.49-0.87) [ figure 1] . CONCLUSION: A novel scoring system based on fetal urinary biochemistry, ultrasound parameters of the fetal kidneys, initial fetal bladder volume and degree of bladder refill 48 hours after bladder tap is suggested. This scoring system seems to be useful in predicting outcome, counseling patients and determining eligibility for fetal intervention. These findings warrant further research given the small sample size.
OBJECTIVE: Fetoscopic tracheal occlusion (FETO) is an experimental prenatal treatment intended to mitigate the pulmonary hypoplasia and hypertension that is a consequence of severe congenital diaphragmatic hernia (CDH). We evaluated outcome of FETO performed at our center and compared these to the largest feasibility study by Jani et al., (Ultrasound Obstet Gyneol 2009; 34:304-10) . STUDY DESIGN: Patients with isolated severe CDH (observed to expected lung to head ratio (O/E LHR)<30%) were prospectively enrolled for FETO in an FDA monitored trial (clinical trials NCT: 02710968). The prenatal and postnatal management and care-path was prospectively defined. Procedure details, obstetric and infant outcomes until discharge were collected. Categorical outcomes were compared using Fishers exact test. RESULTS: 13/52 (25%) screened patients were enrolled between 2015-18 (11 left, 2 right CDH, median O/E LHR 23.4; range 15-24.9%). FETO at 28+6 (27+4 -29+6) weeks gestational age (wks GA), took 12 minutes (range 4-110) and was successful in all cases (vs 7/201 Jani et al, p¼0.9). All balloons remained in situ and contralateral lung increased by a median of 40.5% (21-83.1%, p<0.001, Figure) . All balloons were removed prenatally (vs.Jani:146/ 194, p<0 .05) at 33+5 wks GA (32+1-34+5; median occlusion 33 days, range 17-44). 4 of 13 balloon removals were emergent (vs.Jani: 109/194, p¼0.0893) and in 7/13 by sono guided puncture (vs. Jani, 40/146, p¼0.0587). Four patients had preterm membrane rupture (vs. Jani 99/210, p¼0.3908). 11 infants delivered to date at a median GA of 38+5 wks (33+6-39+4, vs Jani 35+3, p<0.001). We observed one birth <34 wks GA (vs. Jani 65/210, p¼0.012). Patch repair was required for all 11 infants and was performed at a median of 7 days (range 2-15). Extracorporeal membrane oxygenation was required for 6/11 infants for a median duration of 7.5 days (3-19). All infants had pulmonary hypertension; requiring multiple agents. 9/11 infants delivered to date have survived until discharge (vs. Jani 98/205, p<0.05). CONCLUSION: FETO performed in multidisciplinary single center setting is feasible and safe. Despite the severity of CDH we report significantly higher survival than expected in other feasibility studies. This should have a significant impact on the design of a randomized trial in the US for severe CDH. It is unclear if later gestational age at delivery, ECMO availability or standardized postnatal CDH management are the main drivers of improved survival. OBJECTIVE: Fetoscopic tracheal occlusion (FETO) is an experimental prenatal treatment intended to improve the respiratory morbidity and mortality associated with severe congenital diaphragmatic hernia (CDH)). In the US all CDH programs that employ FETO have standardized pediatric care paths that include extracorporeal membrane oxygenation (ECMO). We sought to compare US-FETO outcomes to healthcare settings where ECMO is not uniformly available. STUDY DESIGN: Infant outcome after FETO from a feasibility study at our center (NCT:02710968) and another US Center (Belfort et al., 2017) were aggregated. Similar data were extracted from all published non-US FETO series that are available in PubMed. Gestational age (GA) at FETO, balloon removal and delivery, length of occlusion as well as side of hernia, observed to expected lung to head ratio (O/ E LHR), delivery details and neonatal and infant survival were compared between the two healthcare settings. RESULTS: FETO outcome from 21 CDH infants from the US were compared to 71 reported in six studies from Europe and Brazil. Baseline characteristics and CDH severity were similar between cohorts (table). In the US FETO and balloon removal occurred one week later respectively (p<0.05). Balloon removal was achieved prenatally by fetoscopy more frequently in the US cases (p<0.05). Remaining procedure details were similar. Following balloon removal there were differences in the rate of preterm birth <34 weeks (21/71 vs 2/21) and delivery gestational age (35 vs 36+1 weeks gestation; both p<0.05) in the two care settings. Neonatal survival was higher in the US cohort (p<0.0001), but higher infant survival did not reach significance, Among all significantly divergent variables logistic regression identified the healthcare setting as the primary determinant of neonatal death (r2 0.28, B¼-2.772, p<0.004). CONCLUSION: Survival after FETO for CDH is significantly dependent on the healthcare setting suggesting that postnatal therapies such as ECMO are complementary to overcome the pulmonary hypertension and hypoplasia of severe CDH. Neonatal survival is higher after FETO in ECMO centers. Our findings indicate that randomized trials of fetal therapy for CDH must be powered based on to the specific healthcare setting where this treatment is subsequently intended to be used.
182 Screening for fetal growth restriction in women of advanced maternal age OBJECTIVE: Women classified as advanced maternal age (AMA) have increased rates of fetal growth restriction (FGR) and other adverse outcomes. There is conflicting evidence on whether AMA status in the absence of medical co-morbidities confers increased risk for pathologic growth. Nonetheless, some centers recommend a third trimester growth ultrasound for AMA regardless of medical indication to screen for FGR. This study seeks to determine the rates of FGR in an AMA population with and without a medical indication for a third trimester growth ultrasound. STUDY DESIGN: A retrospective cohort study of AMA women (age >35) who delivered at a large academic tertiary medical center from 2015-2017. Patients were categorized into two groups: medically indicated (MI; defined as pregnancy-induced or chronic hypertension, hyperthyroidism, any drug use, or diabetes) and non-MI (AMA only). Primary outcomes were rates of FGR (EFW <10% on third trimester ultrasound) and small for gestational age (SGA) birthweight. Logistic regression was used to calculate adjusted odds ratios (aOR) stratified by maternal age 35-39 and 40 controlling for race and insurance type. The number needed to screen ([NNS] , incidence x number needed to treat [NNT] ) to prevent one perinatal death was calculated using FGR incidence from this cohort and published NNT data for umbilical artery Doppler to prevent perinatal death. RESULTS: Overall, 1,790 patients met inclusion criteria during the study period with 659 (36.8%) and 1,131 (36.8%) in the MI and non-MI groups respectively; Table 1. The incidence of FGR (1.7% vs 5.0%; p<0.001) and SGA (6.5% vs. 10.1%; p¼.008) were significantly higher in the MI group. Fetal demise rates were not significantly different and 58.3% (14/24) occurred before the third trimester. Adverse obstetric outcomes were significantly more common in the MI group; Table 2 . Stratified by age, the odds of FGR in patients 40 years old was increased in the MI group (aOR 3.0; CI 1.2-7.4) but not in the non-MI group (aOR 0.63; CI 0.1-2.8) using
